While not required for every adverse event, inferential statistical methods can be used both formally and informally to help characterize the safety profile of a new drug and help guide the resulting inferences to the broader population. Examples of probability statements will be shown when used both formally and informally. The particular setting or phase of clinical drug development dictates to some degree whether description with or without formal inference is appropriate.
NaranjoCABustoUSellersEM. Difficulties in assessing adverse drug–reactions in clinical trials. Prog Neuro–psychpharmacol & Biol Psychiatry.1982;6: 651–657.
2.
U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration.Guideline for the Format and Content of the Clinical and Statistical Sections of New Drug Applications.1988;96: 38–40.
3.
PeaceKE. Design, monitoring, and analysis issues relative to adverse events. Drug Inf J.1987;21: 21–28.
4.
O'NeillRT. Assessment of safety. In: PeaceKE, ed. Biopharmaceutical Statistics for Drug Development. New York: Marcel Dekker, Inc.; 1988;543–604.
5.
O'NeillRT. A statistician's perspective on evaluating adverse drug event rates. Presented at the Spring ENAR Biometrics Society Meeting; 1984. March 11–14; Orlando, Florida.
6.
AbtKCockburnITRGueliichAKruppP.Evaluation of adverse drug reactions by means of the life–table method. Drug Inf J.1989;23: 143–149.
7.
DavisBRFurbergCDWilliamsCB. Survival analysis of adverse effects data in the Beta–Blocker Heart Attack Trial. Clin Pharmacol Ther.1987;41: 611–615.
8.
StorerBEKimC.Exact properties of some exact test statistics for comparing two binomial proportions. Journal of the American Statistical Association.1990;85: 146–155.
9.
D'AgostinoRBChaseWBelangerA.The appropriateness of some common procedures for testing the equality of two independent binomial proportions. The American Statistician.1988;42: 198–202.
10.
DozziMRiedwylH.Small sample properties of asymptotic tests for two binomial proportions. Biometric Journal.1984;26: 505–516.
11.
SchwederTSpjotvollE.Plots of p–values to evaluate many tests simultaneously. Biometrika.1982;69: 493–502.
12.
EdwardsSE. Statistical Methods for the Analysis of Adverse Experience Data from Clinical Trials of New Drugs.University of North Carolina; Institute of Statistics Mimeo Series No. 1497T; 1985. Dissertation.
13.
WestfallPHYoungSS. p–value adjustments for multiple tests in multivariate binomial models. Journal of the American Statistical Association.1989;84: 780–786.
14.
SAS Institute Inc.SAS User's Guide: Version 6.10.Cary, NC: SAS Institute Inc.; 1990.
15.
BerryDA. Monitoring accumulating data in a clinical trial. Biometrics.1989;45: 1197–1212.
16.
GoldmanAI. Issues in designing sequential stopping rules for monitoring side effects in clinical trials. Controlled Clinical Trials.1987: 327–337.
17.
NorwoodPKSampsonAR. A statistical methodology for postmarketing surveillance of adverse drug reaction reports. Statistics in Medicine.1988;7: 1023–1030.
18.
KraynakMAKierKL. Selected references on adverse drug reaction reporting. Drug Inf J.1988;22: 573–580.
19.
When a uniquely effective drug is teratogenic: The case of isotretinoin. New England Journal of Medicine.1989;321(11);756–758. Letters to the Editor.
